Danish diabetes giant Novo Nordisk took another step this week in its efforts to establish a presence in nonalcoholic steatohepatitis, or NASH, a metabolic disorder closely related to diabetes that is anticipated to become the leading cause of liver transplants in the US in coming years.
The company Thursday announced it had inked a deal with Ube Industries, a Japanese industrial conglomerate, for worldwide rights to UD-014, a preclinical small molecule drug that it plans to advance as a potential NASH treatment. Novo said Ube’s research showed the compound acted to reduce inflammation. Financial terms weren’t disclosed.
Unlike other fatty liver… Read more »
UNDERWRITERS AND PARTNERS